Robotic vs. Laparoscopic vs. Open Living Donor Hepatectomy

Sponsor
King Faisal Specialist Hospital & Research Center (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT06062706
Collaborator
(none)
3,448
1
2.8
1234.7

Study Details

Study Description

Brief Summary

This will be a study to examine the outcomes of open, laparoscopic, and robotic Living Donor Liver Transplantation (LDLT) procedures. The analysis will encompass 3,448 cases (1,724 donor-recipient pairs) from January 2011 to March 2023, documenting the transition between these surgical techniques, with a noted crossover in 2018.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Donor hepatectomy

Detailed Description

Background: Liver transplantation is a primary treatment for end-stage liver disease, enhancing survival rates and life quality. Living donor liver transplantation (LDLT) has gained prominence due to the scarcity of deceased donor organs. Historically, the open technique dominated living donor hepatectomies. However, advances in minimally invasive surgery (MIS) led to laparoscopic and later robotic procedures. With the introduction of robotic surgery, MIS for complex surgeries improved, offering better precision and ergonomics.

Objective: To compare the short and long-term outcomes of open, laparoscopic, and robotic LDLT, focusing on both donors and recipients.

Methods: Study Design: Retrospective analysis of data from a prospective liver transplant registry, examining three LDLT techniques.

Setting: King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

Participants: All consecutive living donor and recipient pairs undergoing LDLT between January 2011 and March 2023. Exclusions include dual or domino LDLT.

Surgical Techniques: Open, laparoscopic, and robotic techniques used for donor hepatectomies.

Variables: Primary focus on morbidity, conversion rates, and in-hospital mortality for both donors and recipients. Secondary variables will include major complications, graft, and recipient survival rates.

Data Sources and Measurement: Data sourced from a secured, encrypted transplant database, detailing patient data, operation characteristics, and post-op outcomes. Complication severity will be captured using the Clavien-Dindo classification and Comprehensive Complication Index™.

Study Size: Determined by the total number of procedures during the study duration, deemed sufficient for comparison.

Quantitative Variables: Demographics, comorbidities, operational details, post-op and long-term outcomes.

Statistical Methods: Various statistical tests will be employed for comparison, including the Student t, Mann-Whitney U, one-way ANOVA, Fischer and Chi square. Survival will be evaluated using the Kaplan-Meier method. Multivariable binary logistic regression will be employed. All statistical analyses will be conducted using R.

Ethics Approval: Obtained (ID: RAC 2121012) and in accordance with the 1964 Helsinki declaration.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
3448 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Comparison of Outcomes in Robotic vs. Laparoscopic vs. Open Living Donor Hepatectomy: A Single Center Prospective Registry Study
Actual Study Start Date :
Aug 6, 2023
Anticipated Primary Completion Date :
Oct 15, 2023
Anticipated Study Completion Date :
Oct 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Open

Open donor hepatectomy approach: a portion of the liver is resected from a living donor using the traditional open surgical technique, involving a large incision to access the liver directly. This method is most commonly used in living donor liver transplantation nowadays.

Procedure: Donor hepatectomy
Donor hepatectomy is a surgical procedure to resect a portion of the liver from a living donor for transplantation. This usually involved the right lobe, the left lobe or the left lateral section of the liver. Depending on the surgical method, this can be achieved through open, laparoscopic, or robotic-assisted techniques. As for the recipient, liver transplantation involves a total hepatectomy of the diseased liver from the recipient and implantation of the liver graft from the donor. This is typically performed using the open surgical approach.
Other Names:
  • Recipient liver transplantation
  • Laparoscopic

    Laparoscopic donor hepatectomy is a minimally invasive surgical approach where a portion of the liver is resected from a living donor using small incisions and specialized instruments.

    Procedure: Donor hepatectomy
    Donor hepatectomy is a surgical procedure to resect a portion of the liver from a living donor for transplantation. This usually involved the right lobe, the left lobe or the left lateral section of the liver. Depending on the surgical method, this can be achieved through open, laparoscopic, or robotic-assisted techniques. As for the recipient, liver transplantation involves a total hepatectomy of the diseased liver from the recipient and implantation of the liver graft from the donor. This is typically performed using the open surgical approach.
    Other Names:
  • Recipient liver transplantation
  • Robotic

    Robotic donor hepatectomy is an advanced, minimally invasive surgical technique where a portion of the liver is resected from a living donor using robotic instruments. This method is known to provide enhanced precision, improved ergonomics, and superior 3D visualization.

    Procedure: Donor hepatectomy
    Donor hepatectomy is a surgical procedure to resect a portion of the liver from a living donor for transplantation. This usually involved the right lobe, the left lobe or the left lateral section of the liver. Depending on the surgical method, this can be achieved through open, laparoscopic, or robotic-assisted techniques. As for the recipient, liver transplantation involves a total hepatectomy of the diseased liver from the recipient and implantation of the liver graft from the donor. This is typically performed using the open surgical approach.
    Other Names:
  • Recipient liver transplantation
  • Outcome Measures

    Primary Outcome Measures

    1. Donor overall morbidity rate [From date of donor hepatectomy until the date of first hospital discharge assessed up to 90 days postoperatively.]

      Complication rate of any severity according to the Clavien-Dindo Classification

    2. Recipient overall morbidity rate [From date of liver transplantation until the date of hospital discharge assessed up to 90 days postoperatively.]

      Complication rate of any severity according to the Clavien-Dindo Classification

    3. Recipient in-hospital mortality rate [From date of liver transplantation until the date of death assessed up to 90 days post-transplant.]

      Recipient death up to 90 days of follow up

    Secondary Outcome Measures

    1. Donor minimally invasive surgery conversion to open rate [Time from operation start until conversion to open in minutes assessed up to 720 min]

      Includes conversion to open surgery for both laparoscopic and robotic approaches. This does not apply for the open surgical approach.

    2. Donor hospital stay in days [From date of donor hepatectomy until the date of first hospital discharge assessed up to 90 days postoperatively.]

      Number of days the donor was hospitalised during first hospitalisation. Does not include re-hospitalizations.

    3. Recipient Intensive Care Unit (ICU) stay in days [Total number of days hospitalised in ICU, from date of liver transplant until the date of discharge from ICU assessed up to 90 days postoperatively.]

      Total number of days recipient stayed in ICU. This included readmissions to ICU.

    4. Recipient hospital stay in days [From date of liver transplant until the date of first hospital discharge assessed up to 90 days postoperatively.]

      Number of days the recipient was hospitalised. Does not include rehospitalizations.

    5. Graft survival rates [From date of liver transplantation until the date of re-transplantation or recipient death or last follow up assessed up to 120 months post-transplant]

      Graft survival defined as re-transplantation or recipient death.

    6. Recipient survival rates [From date of liver transplantation until the date of recipient death or last follow up assessed up to 120 months post-transplant]

      Recipient survival defined as death post-transplant

    Other Outcome Measures

    1. Major morbidity rates [From date of operation until the date of hospital discharge assessed up to 90 days postoperatively.]

      These include complications of Grade > 2 according to the Clavien-Dindo Classification, i.e., requiring an intervention on the patient requiring organ support in the Intensive Care Unit

    2. Specific complication rates [From date of operation until the date of hospital discharge assessed up to 90 days postoperatively.]

      Infection, bleeding, ascites, vascular, and biliary complications

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    1 Month to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • All donor and recipient pairs that underwent LDLT at the study institution

    • Between 01 January 2011 to 31 March 2023

    • Both adult-to-adult and adult-to-pediatric LDLT are included.

    Exclusion Criteria:
    • Dual and domino LDLT are excluded.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Organ Transplant Center of Excellence, King Faisal Specialist Hospital & Research Centre Riyadh Saudi Arabia 11563

    Sponsors and Collaborators

    • King Faisal Specialist Hospital & Research Center

    Investigators

    • Principal Investigator: Dieter C Broering, MD, PhD, Organ Transplant Center of Excellence, King Faisal Specialist Hospital & Research Centre

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    King Faisal Specialist Hospital & Research Center
    ClinicalTrials.gov Identifier:
    NCT06062706
    Other Study ID Numbers:
    • RAC 2121012
    First Posted:
    Oct 2, 2023
    Last Update Posted:
    Oct 2, 2023
    Last Verified:
    Sep 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 2, 2023